TARO
Taro Pharmaceutical Industries LtdNYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 22, 10:59 AM
    • Taro Pharmaceuticals (TARO -1.8%) appoints Uday Baldota as CEO effective on or about April 1, 2017. He currently serves as EVP & Chief Financial Officer at Sun Pharmaceutical Industries.
    | Tue, Nov. 22, 10:59 AM | 15 Comments
  • Tue, Nov. 8, 5:42 PM
    • Taro Pharmaceutical (NYSE:TARO): Q3 EPS of $3.00
    • Revenue of $228.8M (+3.5% Y/Y)
    • Press Release
    | Tue, Nov. 8, 5:42 PM | 10 Comments
  • Wed, Aug. 10, 5:19 PM
    • Taro Pharmaceutical (NYSE:TARO): FQ1 EPS of $2.59
    • Revenue of $233.8M (+8.6% Y/Y)
    • Press Release
    | Wed, Aug. 10, 5:19 PM | 140 Comments
  • Tue, Jun. 21, 6:06 PM
    • Taro Pharmaceutical Industries' (NYSE:TARO) Chief Financial Officer Michael Kalb will resign effective June 29 to accept a CFO job at another firm. A search for a successor is underway.
    | Tue, Jun. 21, 6:06 PM
  • Fri, May 27, 7:05 AM
    • Taro Pharmaceutical (TARO) FQ4 results: Revenues: $265.1M (+8.6%); R&D Expense: $19.9M (-16.7%); SG&A: $22.6M (+1.8%); Operating Income: $181.7M (+18.4%); Net Income: $115M (-24.6%); EPS: $2.68 (-24.7%).
    • FY2016 results: Revenues: $950.8M (+10.2%); R&D Expense: $71.2M (+8.7%); SG&A: $92.4M (+5.5%); Operating Income: $614.5M (+16.5%); Net Income: $541.5M (+11.5%); EPS: $12.63 (+11.6%); Quick Assets: $576.8M (+19.8%); CF Ops: $395.1M (-2.9%).
    • No guidance given.
    | Fri, May 27, 7:05 AM
  • Thu, May 26, 10:51 PM
    • Taro Pharmaceutical (NYSE:TARO): FQ4 EPS of $2.68
    • Revenue of $265.1M (+8.6% Y/Y)
    | Thu, May 26, 10:51 PM
  • Mon, May 2, 12:06 PM
    • In an example as rare as the targeted disease, Taro Pharmaceutical (TARO -1%) announces that its U.S. subsidiary will make Keveyis (dichlorphenamide) available to distributors at no charge for the treatment of primary periodic paralysis, an ultra-rare and debilitating condition characterized by muscle weakness or paralysis triggered by stimuli such as heat, cold, stress or excitement. Attacks can be due to genetic mutations or abnormal blood potassium levels.
    • Keveyis, approved by the FDA in August 2015, is currently distributed by Diplomat Pharmacy (DPLO -0.9%). The company will cease commercial sales and related promotional activities supporting Keveyis and will continue to absorb all manufacturing costs. It is evaluating the best option to keep pharmacy dispensing fees to patients as low as possible. Currently, patients have an average out-of-pocket cost of less that $25 per month through its Keys2Care support program.
    • The company made its decision in light of the high costs related to reach a limited number of viable patients with the difficult-to-diagnose disorder.
    | Mon, May 2, 12:06 PM | 6 Comments
  • Tue, Mar. 15, 5:36 PM
    • Taro Pharmaceutical (TARO -2.9%) has signed off on a new $250M share repurchase program.
    • The company's not setting a time period or expiration date for the program. As typical, purchases can be made on the open market, negotiated transactions, 10b5-1 trading plans or otherwise.
    • At its last report, Taro had $1.18B in cash on its balance sheet, with no debt.
    • Shares are flat in after-hours trading.
    | Tue, Mar. 15, 5:36 PM | 8 Comments
  • Wed, Feb. 10, 5:37 PM
    • Taro Pharmaceutical (NYSE:TARO): Q4 EPS of $4.41
    • Revenue of $258.3M (+8.7% Y/Y)
    | Wed, Feb. 10, 5:37 PM | 8 Comments
  • Aug. 10, 2015, 9:40 AM
    • The FDA approves Taro Pharmaceutical Industries' (TARO +0.5%) Keveyis (dichlorphenamide) 50 mg tablets for the treatment of primary hyperkalemic (excess potassium in the blood) and hypokalemic (reduced levels of potassium in the blood) periodic paralysis, a group of rare inherited disorders that are characterized by episodes of extreme muscle weakness during which sufferers are unable to move muscles in the arms and legs for hours or days. The disorder affects ~5,000 Americans.
    • The product launch will commence this quarter.
    | Aug. 10, 2015, 9:40 AM
  • Aug. 6, 2015, 5:43 PM
    • Taro Pharmaceutical (NYSE:TARO): FQ1 EPS of $2.42
    • Revenue of $215.3M (+65.4% Y/Y)
    | Aug. 6, 2015, 5:43 PM
  • May 27, 2015, 7:52 AM
    • Taro Pharmaceutical (TARO -0.4%) FQ4 results: Revenues: $244.2M (+30.4%); COGS: $44.5M (-2.8%); R&D Expense: $23.9M (+81.1%); SG&A: $22.2M (-16.5%); Operating Income: $153.5M (+51.2%); Net Income: $152.6M (+70.1%); EPS: $3.56 (+69.5%).
    • FY2015 results: Revenues: $862.9M (+13.6%); COGS: $186.4M (+4.0%); R&D Expense: $65.5M (+18.2%); SG&A: $87.6M (-4.5%); Operating Income: $527.6M (+22.6%); Net Income: $485.6M (+34.4%); EPS: $11.32 (+38.9%); Quick Assets: $920M (+45.5%).
    • No guidance given.
    | May 27, 2015, 7:52 AM
  • May 26, 2015, 10:13 PM
    • Taro Pharmaceutical (NYSE:TARO): FQ4 EPS of $3.56
    • Revenue of $244.2M (+30.5% Y/Y)
    | May 26, 2015, 10:13 PM
  • Apr. 8, 2015, 11:47 AM
    • Mylan (MYL +10.4%) submits a non-binding proposal to Perrigo (PRGO +27.6%) to acquire it for $205 per share in a cash-and-stock deal. If consummated, the combined company would generate over $15B in annual sales.
    • Generic drug-related tickers: (LCI +3%)(AKRX +4.4%)(MNK +2.8%)(IPXL +2.3%)(TARO +2.3%)(TEVA +3.2%)
    | Apr. 8, 2015, 11:47 AM | 13 Comments
  • Feb. 11, 2015, 10:24 AM
    • Taro Pharmaceutical (TARO +2%) FQ3 results: Revenues: $237.7M (+11.3%); COGS: $44.2M (+7.5%); R&D Expense: $12.8M (-15.2%); SG&A: $21.3M (-2.7%); Operating Income: $159.3M (+18.1%); Net Income: $142.5M (+23.3%); EPS: $3.33 (+28.6%); Quick Assets: $738M (+16.7%); CF Ops: $192.8M (-29.6%).
    • No guidance given.
    | Feb. 11, 2015, 10:24 AM
  • Feb. 10, 2015, 4:51 PM
    • Taro Pharmaceutical (NYSE:TARO): FQ3 EPS of $3.33.
    • Revenue of $237.7M (+11.3% Y/Y).
    | Feb. 10, 2015, 4:51 PM | 1 Comment